Research · Sep 3, 2026
[TECH] Bio-Techne Thesis 2026: Spatial Biology Drives Life Sciences Reagent Recovery
Bio-Techne Corporation (NASDAQ: TECH) FY2025 (fiscal year ending June 2026) revenue ~$1.18-1.22B (+5-8%) with adj. EPS ~$1.30-1.80 reflecting continued post-2024 biopharma R&D spending compression similar to Charles River Labs + selected April 2024 Lunaphore Technologies $130M spatial biology acquisition partial-year contribution + selected Protein Sciences leadership ($830M; R&D Systems category-leading) + selected Diagnostics & Genomics + ACD RNAscope spatial biology + selected operational continuity under new CEO Kim Kelderman (~1.5-year tenure since February 2024). Leading global life sciences research reagents + diagnostics + ProteinSimple instruments firm. Founded 1976 as Research and Diagnostic Systems (R&D Systems) by selected founders in Minneapolis Minnesota (~49-year heritage; selected initial focus on selected protein research reagents); selected various rebrands including Bio-Techne Corporation post-2014 (selected reflecting platform expansion beyond core R&D Systems brand); IPO 1989 NASDAQ; selected various transformative acquisitions including 2014 ProteinSimple $300M (Western blot instruments) + 2018 Advanced Cell Diagnostics $250M (RNAscope spatial biology) + 2018 Exosome Diagnostics + 2020 Asuragen $235M (genomics) + April 2024 Lunaphore Technologies $130M (spatial biology). Headquartered in Minneapolis Minnesota; ~3,200+ employees globally with ~$1.18-1.22B revenue. Two reporting segments: Protein Sciences ~70% revenue ($830M — R&D Systems leading brand of proteins + antibodies + ELISA reagents ~$700M+ + ProteinSimple instruments ~$130M+ Wes + Simple Western automated Western blot) + Diagnostics & Genomics ~30% ($350M — diagnostic IVD reagents + ACD RNAscope spatial biology ~$100M+ + ExoDx prostate cancer urine test + GenoMark molecular diagnostic). Spatial biology catalyst: April 2024 Lunaphore Technologies $130M acquisition (Switzerland-based spatial biology firm; selected COMET sequential multiplexed immunofluorescence platform for spatial proteomics + selected fully automated tissue staining); ~$15-20M Lunaphore standalone revenue at acquisition; ~$30M+ FY2025 revenue contribution; ~$50-100M FY2026 revenue trajectory; selected spatial biology TAM ~$1B+ growing 25-30% annually; selected major competitors 10x Genomics + NanoString Technologies + Akoya Biosciences. Biopharma R&D cycle: post-2024 biopharma R&D spending compression similar to Charles River Labs (~30-40% biopharma R&D budget tightening from peak); post-2024 biotech VC + IPO recovery emerging (~$8B-$10B FY2024 trough vs ~$15B FY2022 peak). CEO Kim Kelderman since February 2024 (succeeded Charles Kummeth CEO 2013-February 2024 retired who led 2013-2024 strategic transformation including 2014 ProteinSimple + 2018 ACD; Kelderman ex-Bio-Techne CFO 2017-February 2024 + ex-various roles 1996-2017 + ~25-year company career). Capital return: ~$1.28-1.36 annual dividend FY2025 (~$0.32-0.34/quarter; ~7+ consecutive year continuous increases); $0.5-1B buyback program; investment-grade Baa2/BBB credit ratings; FCF $200-300M. FY2026 thesis: Lunaphore COMET spatial biology ramp + Protein Sciences biopharma R&D stabilization + ~8-year dividend track + Diagnostics & Genomics growth. Risks: major biopharma R&D cycle deterioration, Lunaphore competitive substitution, ProteinSimple competitive intensity from Thermo Fisher, currency translation severe.